Business Context and Reporting Period
This Form 8-K, dated June 30, 2011, reports the completion of a major acquisition by BioZone Pharmaceuticals, Inc. (formerly International Surf Resorts, Inc.). The Company, incorporated in Nevada, has pivoted from its prior business to become an integrated pharmaceutical company. The filing details the acquisition of the "BioZone Labs Group," comprising BioZone Laboratories, Inc., Equalan Pharmaceuticals, LLC, Equachem LLC, and a 45% interest in BetaZone LLC. The Company now operates two primary business lines: a healthcare product business (OTC, cosmetics, contract manufacturing) and a pharmaceutical business focused on generic prescription drugs utilizing proprietary drug delivery technologies (QuSomes, LiquaVail, HyperSorb, EquaSomes).
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or margin data for the reporting period. Financial statements for the acquired entities are scheduled to be filed within 71 days. Key transaction metrics include:
- Consideration: The Company issued an aggregate of 21,000,000 shares of restricted common stock to acquire the BioZone Labs Group entities.
- Share Issuance Breakdown:
- BioZone Labs (100%): 19,266,055 shares
- Equalan (100%): 1,027,523 shares
- Equachem (100%): 385,321 shares
- BetaZone (45%): 321,101 shares
- Outstanding Shares: As of July 7, 2011, there were 67,029,396 shares of common stock issued and outstanding.
- Related Party Rent: The Company rents a 20,000 sq. ft. manufacturing facility from Executive Vice President Daniel Fisher. Rent expense was $291,528 for the years ended December 31, 2010 and 2009.
Material Changes Versus Prior Period
The most significant change is the fundamental transformation of the Company's business model. Prior to June 30, 2011, the Company's principal business was marketing dermatological products under the Baker Cummins trade name (acquired in May 2011). Following the June 30 acquisition, the Company now owns the manufacturing facilities, R&D capabilities, and proprietary technology of the BioZone Labs Group. Additionally, the Company's executive leadership and board of directors were reconstituted effective June 30, 2011, with the appointment of Daniel Fisher and Brian Keller to the Board and the appointment of Brian Keller as President and Chief Scientific Officer.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management intends to grow the healthcare product business by expanding proprietary brands and contract manufacturing. For the pharmaceutical business, the strategy involves seeking FDA approval for generic prescription drugs via 505(b)(2) applications or ANDAs, leveraging proprietary lipid vesicle technology to improve drug stability and bioavailability.
Opko Options: In connection with the acquisition, Opko Health, Inc. was granted options to purchase up to 8,645,000 shares of the Company's common stock at $1.00 per share (with a portion of the Fisher option exercisable at VWAP). These options are subject to 18-month lock-up provisions.
Risks and Contingencies:
- Regulatory Risk: The business is highly regulated by the FDA. Failure to comply with cGMP or obtain necessary approvals (ANDA/NDA) could halt operations.
- Customer Concentration: Approximately 50% of revenue in 2009 and 2010 was generated by three customers in the contract manufacturing segment.
- Stock Liquidity: The stock trades on the OTC Bulletin Board and is subject to "Penny Stock" rules, which may limit liquidity and market price.
- Intellectual Property: Success depends on maintaining patent protection for proprietary technologies; litigation risks are significant.
- Financial Statements: Audited financial statements for the acquired entities are not yet included in this filing and are due within 71 days.
Investor Verification Checklist
- Verify the upcoming filing of audited financial statements for BioZone Labs, Equalan, Equachem, and BetaZone (due within 71 days of this report).
- Confirm the status of the Opko Health, Inc. stock options and the potential dilution impact of the 8,645,000 shares subject to option.
- Review the specific terms of the 18-month lock-up agreements restricting the sale of shares issued to the BioZone Labs Group sellers.
- Assess the dependency on the three major contract manufacturing customers representing 50% of historical revenue.
- Monitor FDA compliance status, specifically regarding the cGMP manufacturing facility rented from a related party (Daniel Fisher).